News

Zepbound outperforms Wegovy in head-to-head weight loss trial
Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...
Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial
Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's (NVO ...
TipRanks on MSN2d
Eli Lilly’s Zepbound Defeats Novo Nordisk’s Wegovy Once Again
Preview in new tab Pharmaceutical giants Eli Lilly ($LLY) and Novo Nordisk ($NVO) are engaged in a head-to-head battle to ...
Mirage News4h
Zepbound Outduels Wegovy In Weight-loss Clinical Trial
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...
EconoTimes2d
Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial
Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...
U.S. News & World Report2d
Zepbound Beats Wegovy for Weight Loss in First Head-To-Head Trial of Blockbuster Drugs
Zepbound Beats Wegovy for Weight Loss in First Head-To ... While tirzepatide won out in what Aronne said many view as “a drag race of efficacy,” both are important tools for treating obesity ...
The Boston Globe3d
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
While tirzepatide won out in what Aronne said many view as “a drag race of efficacy ... tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or ...